BWXT Medical and NorthStar Medical Radioisotopes Sign Supply Agreement Supporting Actinium-225 Production
BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc. (NYSE: BWXT) and NorthStar Medical Radioisotopes, LLC (NorthStar) today announced that they have signed a Master Services Agreement (MSA), which will facilitate the production of actinium-225 (Ac-225), a critical medical isotope used to kill cancer cells while minimizing the impact to healthy tissues.
BWXT to Evaluate Locations for Building New Nuclear TRISO Fuel Production Facility to Support Advanced Reactor Deployment
(LYNCHBURG, Va. – July 18, 2024) – BWX Technologies, Inc. (NYSE: BWXT) is evaluating locations for a potential new TRISO nuclear fuel production facility to support anticipated future demand for advanced reactor deployment. As part of this effort, BWXT’s Advanced Technologies subsidiary has signed a cooperation agreement with the State of Wyoming to evaluate the requirements for siting a fuel fabrication facility in the state. The roughly 18-month effort will evaluate such matters as potential factory locations, product specifications, facility design and engineering, estimated capital expenditures and operating costs, staffing and worker skill requirements, supply chain necessities, licensing and other requirements.
BWXT Awarded Phase Two of Microreactor Evaluation Contract for State of Wyoming
(LYNCHBURG, Va. – June 17, 2024) – BWX Technologies, Inc. (NYSE: BWXT) today announced the award of the second phase of a contract with the Wyoming Energy Authority to assess the viability of deploying small-scale nuclear reactors in the state as a source of resilient and reliable energy to augment existing power generation resources.
BWXT-led Team Awarded $30 Billion Management and Operating Contract for National Nuclear Security Administration’s Pantex Plant
(LYNCHBURG, Va. – June 14, 2024) – BWX Technologies, Inc. (NYSE: BWXT) today announced a contract award from the U.S. Department of Energy, National Nuclear Security Administration (DOE/NNSA) for management and operations of the Pantex Plant. Following an initial term of five years, NNSA has the ability to award three additional five-year option periods. If all contract options are exercised, the contract will span 20 years at a funding level of approximately $30 billion.
BWXT Medical Submits Drug Master File for Actinium-225 API to U.S. Food and Drug Administration
BWXT Medical Ltd. has submitted a Drug Master File (DMF) to the U.S. Drug and Food Administration (FDA) for No Carrier Added (n.c.a.) Actinium-225 (Ac-225) Active Pharmaceutical Ingredient.
BWXT employees trained as Nuclear Ambassadors
BWX Technologies, Inc. (BWXT) has partnered with the American Nuclear Society to offer customized ANS Nuclear Ambassadors training to BWXT employees.
BWXT Names John Lucio as Senior Director for Government Relations
BWX Technologies, Inc. has hired John Lucio as a senior director for government relations.
BWXT Named First Member of GE Vernova Nuclear’s Small Modular Reactor Supplier Group
BWXT Canada Ltd., a subsidiary of BWX Technologies, Inc. has been selected as the first qualified supply chain company to join the GE Vernova nuclear business’ supplier group that will advance the global deployment of the BWRX-300 small modular reactor (SMR).
BWXT Announces Expansion of Cambridge Manufacturing Plant to Support Global Nuclear Power Market
BWX Technologies, Inc. (NYSE: BWXT) announced an investment to expand its Cambridge manufacturing plant.